Patents by Inventor Joseph C. Glorioso
Joseph C. Glorioso has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11883448Abstract: The present invention provides a recombinant oncolytic Herpes Simplex Virus (oHSV) comprising a non-HSV ligand specific for a molecule (protein, lipid, or carbohydrate determinant) present on the surface of a cell (such as a cancer cell) and one or more copies of one or more microRNA target sequences inserted into one or more HSV gene loci, preferably one or more HSV gene(s) required for replication of HSV in normal (i.e., non-cancerous) cells. The invention further provides stocks and pharmaceutical compositions comprising the inventive oHSV and methods for killing tumor cells employing the inventive oHSV.Type: GrantFiled: August 5, 2020Date of Patent: January 30, 2024Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: Hiroaki Uchida, Justus B. Cohen, Joseph C. Glorioso, III, Paola Grandi
-
Patent number: 11725038Abstract: The invention provides a method of modulating electrophysiological activity of an excitable cell. The method involves causing exogenous expression of a glycine receptor (GlyR) protein in an excitable cell of a subject. Thereafter, the excitable cell is exposed to an allosteric modulator of the GlyR protein. Modulation of the exogenous GlyR protein (an ion channel) in response to the allosteric modulator modulates the electrophysiological activity of the excitable cell. The method can be used to control pain in a subject. The invention further provides a replication-defective HSV vector comprising an expression cassette encoding a GlyR protein, stocks and pharmaceutical compositions containing such vectors, and a transgenic animal.Type: GrantFiled: May 22, 2020Date of Patent: August 15, 2023Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: Michael Cascio, Joseph C. Glorioso, III, James R. Goss, David Krisky
-
Patent number: 11427625Abstract: Provided is a recombinant viral vector that expresses a NKG2D activating ligand, such as a UL-16 binding protein. When introduced into a cancer cell, the vector can cause expression of the NKG2D activating ligand, thereby overcoming repression of NK-mediated (or other effector cell, e.g., macrophage) cytotoxicity and causing effector cell-mediated death of the cancer cell. Expression of the NKG2D activating ligand can be controlled by a miRNA present in greater concentration in noncancerous cells than in cancer cells, which can permit selective expression of the ligand in cancer cells and reduced cytotoxicity toward noncancerous cells. The vector can cause expression of an oncolytic factor. When formulated into a pharmaceutical composition and administered to a patient, the vector can be used to treat cancer. The cancer can be a glioma, such as glioblastoma including one with an isocitrate dehydrogenase (IDH) mutation. The vector can be a herpes simplex virus vector, among others.Type: GrantFiled: June 14, 2017Date of Patent: August 30, 2022Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Paola Grandi, Ndukaku Mgbechinyere Amankulor, Joseph C. Glorioso, III
-
Patent number: 11419926Abstract: In one embodiment, the invention provides an HSV vector comprising a mutant gB and/or a mutant gH glycoprotein, where the viral envelope further comprises a non-native ligand specific for a protein present on the surface of a predetermined cell type. In another embodiment, the invention provides an HSV vector comprising (a) a mutant gC and/or gD envelope glycoprotein which comprises a non-native ligand specific for a protein present on the surface of a predetermined cell type; and (b) a mutant envelope glycoprotein other than gD.Type: GrantFiled: May 20, 2019Date of Patent: August 23, 2022Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Joseph C. Glorioso, III, Hiroaki Uchida, Justus B. Cohen
-
Publication number: 20220213508Abstract: Disclosed is a method for administering a transgene into a fibroblast in a subject comprising: a) providing a herpes simplex virus (HSV) comprising a recombinant herpes simplex virus genome, wherein said recombinant herpes simplex virus genome comprises one or more transgenes encoding a polypeptide to be expressed in said fibroblast; and b) providing a pharmaceutically acceptable carrier; wherein said HSV has reduced cytotoxicity as compared to a wild-type herpes simplex virus.Type: ApplicationFiled: March 24, 2022Publication date: July 7, 2022Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Joseph C. Glorioso, III, Justus Cohen, Yoshitaka Miyagawa, David Krisky, James Wechuck, Darren Wolfe
-
Publication number: 20210138007Abstract: The present invention provides a recombinant oncolytic Herpes Simplex Virus (oHSV) comprising a non-HSV ligand specific for a molecule (protein, lipid, or carbohydrate determinant) present on the surface of a cell (such as a cancer cell) and one or more copies of one or more microRNA target sequences inserted into one or more HSV gene loci, preferably one or more HSV gene(s) required for replication of HSV in normal (i.e., non-cancerous) cells. The invention further provides stocks and pharmaceutical compositions comprising the inventive oHSV and methods for killing tumor cells employing the inventive oHSV.Type: ApplicationFiled: August 5, 2020Publication date: May 13, 2021Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Hiroaki Uchida, Justus B. Cohen, Joseph C. Glorioso, III, Paola Grandi
-
Publication number: 20210121513Abstract: Provided herein are antigenically stealthed HSV particles, and methods of use of the antigenically-stealthed HSV particles.Type: ApplicationFiled: May 31, 2019Publication date: April 29, 2021Inventors: Joseph C. Glorioso, III, Gary H. Cohen, Doina Atanasiu, Tina Marie Cairns, Bonnie Lynn Hall, Justus B. Cohen, Ceren Tuzmen
-
Publication number: 20210040172Abstract: The invention provides a method of modulating electrophysiological activity of an excitable cell. The method involves causing exogenous expression of a glycine receptor (GlyR) protein in an excitable cell of a subject. Thereafter, the excitable cell is exposed to an allosteric modulator of the GlyR protein. Modulation of the exogenous GlyR protein (an ion channel) in response to the allosteric modulator modulates the electrophysiological activity of the excitable cell. The method can be used to control pain in a subject. The invention further provides a replication-defective HSV vector comprising an expression cassette encoding a GlyR protein, stocks and pharmaceutical compositions containing such vectors, and a transgenic animal.Type: ApplicationFiled: May 22, 2020Publication date: February 11, 2021Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Michael Cascio, Joseph C. Glorioso, III, James R. Goss, David Krisky
-
Patent number: 10851354Abstract: The invention provides a method for ameliorating chronic pain signaling involving transient receptor potential cation channel subfamily V member 1 (TRPV1) by expressing PP1? in neurons. The invention also provides HSV vectors for expressing PP1? within neurons and compositions comprising such vectors.Type: GrantFiled: November 21, 2018Date of Patent: December 1, 2020Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: William F. Goins, Joseph C. Glorioso, III, Justus Bernard Cohen, Bonnie L. Reinhart
-
Patent number: 10696727Abstract: The invention provides a method of modulating electrophysiological activity of an excitable cell. The method involves causing exogenous expression of a glycine receptor (GlyR) protein in an excitable cell of a subject. Thereafter, the excitable cell is exposed to an allosteric modulator of the GlyR protein. Modulation of the exogenous GlyR protein (an ion channel) in response to the allosteric modulator modulates the electrophy-stological activity of the excitable cell. The method can be used to control pain in a subject. The invention further provides a replication-defective HSV vector comprising an expression cassette encoding a GlyR protein, stocks and pharmaceutical compositions containing such vectors, and a transgenic animal.Type: GrantFiled: December 29, 2014Date of Patent: June 30, 2020Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Michael Cascio, Joseph C. Glorioso, III, James R. Goss, David Krisky
-
Publication number: 20200148742Abstract: Provided is a recombinant viral vector that expresses a NKG2D activating ligand, such as a UL-16 binding protein. When introduced into a cancer cell, the vector can cause expression of the NKG2D activating ligand, thereby overcoming repression of NK-mediated (or other effector cell, e.g., macrophage) cytotoxicity and causing effector cell-mediated death of the cancer cell. Expression of the NKG2D activating ligand can be controlled by a miRNA present in greater concentration in noncancerous cells than in cancer cells, which can permit selective expression of the ligand in cancer cells and reduced cytotoxicity toward noncancerous cells. The vector can cause expression of an oncolytic factor. When formulated into a pharmaceutical composition and administered to a patient, the vector can be used to treat cancer. The cancer can be a glioma, such as glioblastoma including one with an isocitrate dehydrogenase (IDH) mutation. The vector can be a herpes simplex virus vector, among others.Type: ApplicationFiled: June 14, 2017Publication date: May 14, 2020Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Paola Grandi, Ndukaku Mgbechinyere Amankulor, Joseph C. Glorioso, III
-
Publication number: 20200147189Abstract: In one embodiment, the invention provides an HSV vector comprising a mutant gB and/or a mutant gH glycoprotein, where the viral envelope further comprises a non-native ligand specific for a protein present on the surface of a predetermined cell type. In another embodiment, the invention provides an HSV vector comprising (a) a mutant gC and/or gD envelope glycoprotein which comprises a non-native ligand specific for a protein present on the surface of a predetermined cell type; and (b) a mutant envelope glycoprotein other than gD.Type: ApplicationFiled: May 20, 2019Publication date: May 14, 2020Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Joseph C. Glorioso, III, Hiroaki Uchida, Justus B. Cohen
-
Patent number: 10576115Abstract: The present invention provides a recombinant herpes simplex virus (HSV), comprising (a) a mutation of the glycoprotein B (gB) at position 285 or 549, (b) a plurality of copies of one or more microRNA target sequences inserted into a locus of an HSV gene required for HSV replication, wherein said target sequence is the reverse complement of microRNA miR-124 and wherein said target sequence is present in the ICP4 gene, and (c) a transgene encoding a matrix metalloproteinase. The present invention also provides a method of killing a cancerous cell using a recombinant HSV according to the invention and a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a recombinant HSV according to the invention.Type: GrantFiled: November 14, 2018Date of Patent: March 3, 2020Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Hiroaki Uchida, Justus B. Cohen, Joseph C. Glorioso, III, Paola Grandi
-
Publication number: 20190292530Abstract: The invention provides a method for ameliorating chronic pain signaling involving transient receptor potential cation channel subfamily V member 1 (TRPV1) by expressing PP1? in neurons. The invention also provides HSV vectors for expressing PP1? within neurons and compositions comprising such vectors.Type: ApplicationFiled: November 21, 2018Publication date: September 26, 2019Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: William F. Goins, Joseph C. Glorioso, III, Justus Bernard Cohen, Bonnie L. Reinhart
-
Publication number: 20190276845Abstract: In one embodiment, the invention provides a herpes simplex virus (HSV) vector that does not express toxic HSV genes in non-complementing cells and which comprises a genome comprising one or more transgenes, wherein the vector is capable of expression of a transgene for at least 28 days in non-complementing cells. The invention also relates to viral stocks of the inventive vectors, compositions thereof suitable for use therapeutically or for in vitro applications, and methods relating thereto. In another aspect, the invention provides a complementing cell engineered to express ICP4 and ICP27 when the cell is infected with HSV for the production of the inventive vector.Type: ApplicationFiled: November 26, 2018Publication date: September 12, 2019Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Joseph C. Glorioso, III, Justus Cohen, Yoshitaka Miyagawa, David Krisky, James Wechuck, Darren Wolfe
-
Publication number: 20190262410Abstract: The present invention provides a recombinant herpes simplex virus (HSV), comprising (a) a mutation of the glycoprotein B (gB) at position 285 or 549, (b) a plurality of copies of one or more microRNA target sequences inserted into a locus of an HSV gene required for HSV replication, wherein said target sequence is the reverse complement of microRNA miR-124 and wherein said target sequence is present in the ICP4 gene, and (c) a transgene encoding a matrix metalloproteinase. The present invention also provides a method of killing a cancerous cell using a recombinant HSV according to the invention and a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a recombinant HSV according to the invention.Type: ApplicationFiled: November 14, 2018Publication date: August 29, 2019Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Hiroaki Uchida, Justus B. Cohen, Joseph C. Glorioso, III, Paola Grandi
-
Patent number: 10328136Abstract: In one embodiment, the invention provides an HSV vector comprising a mutant gB and/or a mutant gH glycoprotein, where the viral envelope further comprises a non-native ligand specific for a protein present on the surface of a predetermined cell type. In another embodiment, the invention provides an HSV vector comprising (a) a mutant gC and/or gD envelope glycoprotein which comprises a non-native ligand specific for a protein present on the surface of a predetermined cell type; and (b) a mutant envelope glycoprotein other than gD.Type: GrantFiled: January 18, 2017Date of Patent: June 25, 2019Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Joseph C. Glorioso, III, Hiroaki Uchida, Justus B. Cohen
-
Patent number: 10201575Abstract: The present invention provides a recombinant oncolytic Herpes Simplex Virus (oHSV) comprising a non-HSV ligand specific for a molecule (protein, lipid, or carbohydrate determinant) present on the surface of a cell (such as a cancer cell) and a plurality of copies of one or more microRNA target sequences inserted into one or more HSV gene loci, preferably one or more HSV gene(s) required for replication of HSV in normal (i.e., non-cancerous) cells, and a deletion of the internal repeat (joint) region in the HSV genome comprising one copy of the ICP0, ICP34.5, LAT, and ICP4 genes and the ICP47 promoter. The invention further provides stocks and pharmaceutical compositions comprising the inventive oHSV and methods for killing tumor cells employing the inventive oHSV.Type: GrantFiled: October 28, 2014Date of Patent: February 12, 2019Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Hiroaki Uchida, Justus B. Cohen, Joseph C. Glorioso, III, Paola Grandi
-
Patent number: 10188686Abstract: The present invention provides a recombinant oncolytic Herpes Simplex Virus (oHSV) comprising a non-HSV ligand specific for a molecule (protein, lipid, or carbohydrate determinant) present on the surface of a cell (such as a cancer cell) and one or more copies of one or more microRNA target sequences inserted into one or more HSV gene loci, preferably one or more HSV gene(s) required for replication of HSV in normal (i.e., non-cancerous) cells. The invention further provides stocks and pharmaceutical compositions comprising the inventive oHSV and methods for killing tumor cells employing the inventive oHSV.Type: GrantFiled: July 7, 2016Date of Patent: January 29, 2019Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Hiroaki Uchida, Justus B. Cohen, Joseph C. Glorioso, III, Paola Grandi
-
Patent number: 10174341Abstract: The invention provides a herpes simplex virus (HSV) vector that does not express toxic HSV genes in non-complementing cells and which comprises a genome comprising one or more transgenes, wherein the vector is capable of expression of a transgene for at least 28 days in non-complementing cells. The disclosed vectors include vectors having deletions in the genes ICP0, ICP4, TCP22, TCP27 and TCP47, or alternative inactivating mutations, or vectors which express one or more of these genes with modified kinetics. The invention also relates to viral stocks of the inventive vectors, compositions thereof suitable for use therapeutically or for in vitro applications, and methods relating thereto. In another aspect, the invention provides a complementing cell, in particular a U20S cell, engineered to express ICP4 and ICP27 when the cell is infected with HSV for the production of the inventive vector. Said cells are disclosed as naturally complementing ICP0.Type: GrantFiled: July 17, 2014Date of Patent: January 8, 2019Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Joseph C. Glorioso, III, Justus Cohen, Yoshitaka Miyagawa, David Krisky, James Wechuck, Darren Wolfe